Assessing Onchocerca volvulus Intensity of Infection and Genetic Diversity Using Mitochondrial Genome Sequencing of Single Microfilariae Obtained before and after Ivermectin Treatment
- PMID: 37513818
- PMCID: PMC10385737
- DOI: 10.3390/pathogens12070971
Assessing Onchocerca volvulus Intensity of Infection and Genetic Diversity Using Mitochondrial Genome Sequencing of Single Microfilariae Obtained before and after Ivermectin Treatment
Abstract
Onchocerciasis is a neglected tropical disease targeted for elimination using ivermectin mass administration. Ivermectin kills the microfilariae and temporarily arrests microfilariae production by the macrofilariae. We genotyped 436 microfilariae from 10 people each in Ituri, Democratic Republic of the Congo (DRC), and Maridi County, South Sudan, collected before and 4-5 months after ivermectin treatment. Population genetic analyses identified 52 and 103 mitochondrial DNA haplotypes among the microfilariae from DRC and South Sudan, respectively, with few haplotypes shared between people. The percentage of genotype-based correct assignment to person within DRC was ~88% and within South Sudan ~64%. Rarefaction and extrapolation analysis showed that the genetic diversity in DRC, and even more so in South Sudan, was captured incompletely. The results indicate that the per-person adult worm burden is likely higher in South Sudan than DRC. Analyses of haplotype data from a subsample (n = 4) did not discriminate genetically between pre- and post-treatment microfilariae, confirming that post-treatment microfilariae are not the result of new infections. With appropriate sampling, mitochondrial haplotype analysis could help monitor changes in the number of macrofilariae in a population as a result of treatment, identify cases of potential treatment failure, and detect new infections as an indicator of continuing transmission.
Keywords: drug studies; elimination; epidemiology; macrofilariae; microfilariae; monitoring; onchocerciasis; population genetics.
Conflict of interest statement
A.C.K was a staff member of WHO/TDR at the time this work was conducted. The authors declare no other conflict of interest.
Figures





Similar articles
-
Procedure for Handling and Storage of Onchocerca volvulus Microfilariae Obtained from Skin Snips for Downstream Genetic Work.Trop Med Infect Dis. 2023 Sep 12;8(9):445. doi: 10.3390/tropicalmed8090445. Trop Med Infect Dis. 2023. PMID: 37755906 Free PMC article.
-
Effect of a single dose of 8 mg moxidectin or 150 μg/kg ivermectin on O. volvulus skin microfilariae in a randomized trial: Differences between areas in the Democratic Republic of the Congo, Liberia and Ghana and impact of intensity of infection.PLoS Negl Trop Dis. 2022 Apr 27;16(4):e0010079. doi: 10.1371/journal.pntd.0010079. eCollection 2022 Apr. PLoS Negl Trop Dis. 2022. PMID: 35476631 Free PMC article. Clinical Trial.
-
Effect of Ivermectin Treatment on the Frequency of Seizures in Persons with Epilepsy Infected with Onchocerca volvulus.Pathogens. 2020 Dec 31;10(1):21. doi: 10.3390/pathogens10010021. Pathogens. 2020. PMID: 33396221 Free PMC article.
-
Onchocerciasis-associated epilepsy: an update and future perspectives.Trends Parasitol. 2023 Feb;39(2):126-138. doi: 10.1016/j.pt.2022.11.010. Epub 2022 Dec 15. Trends Parasitol. 2023. PMID: 36528471 Review.
-
Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy.Acta Trop. 2011 Sep;120 Suppl 1:S100-8. doi: 10.1016/j.actatropica.2010.08.009. Epub 2010 Aug 27. Acta Trop. 2011. PMID: 20801094 Review.
Cited by
-
Genetic structuring and estimation of reproductive adults in Onchocerca volvulus: A genome-wide analysis across hosts and regions.PLoS Negl Trop Dis. 2025 Jul 1;19(7):e0013221. doi: 10.1371/journal.pntd.0013221. eCollection 2025 Jul. PLoS Negl Trop Dis. 2025. PMID: 40591654 Free PMC article.
-
Procedure for Handling and Storage of Onchocerca volvulus Microfilariae Obtained from Skin Snips for Downstream Genetic Work.Trop Med Infect Dis. 2023 Sep 12;8(9):445. doi: 10.3390/tropicalmed8090445. Trop Med Infect Dis. 2023. PMID: 37755906 Free PMC article.
-
Presumed Onchocerciasis Chorioretinitis Spilling over into North America, Europe and Middle East.Diagnostics (Basel). 2023 Dec 8;13(24):3626. doi: 10.3390/diagnostics13243626. Diagnostics (Basel). 2023. PMID: 38132210 Free PMC article.
-
Recurrence of microfilaraemia after triple-drug therapy for lymphatic filariasis in Samoa: Recrudescence or reinfection?Int J Infect Dis. 2025 Mar;152:107809. doi: 10.1016/j.ijid.2025.107809. Epub 2025 Jan 30. Int J Infect Dis. 2025. PMID: 39892502 Free PMC article.
References
-
- World Health Organization Elimination of human onchocerciasis: Progress report, 2020. Wkly. Epidemiol. Rec. 2021;46:557–567.
-
- Chesnais C.B., Nana-Djeunga H.C., Njamnshi A.K., Lenou-Nanga C.G., Boulle C., Bissek A.Z., Kamgno J., Colebunders R., Boussinesq M. The temporal relationship between onchocerciasis and epilepsy: A population-based cohort study. Lancet Infect. Dis. 2018;18:1278–1286. doi: 10.1016/S1473-3099(18)30425-0. - DOI - PubMed
-
- Colebunders R., Njamnshi A.K., van Oijen M., Mukendi D., Kashama J.M., Mandro M., Gumisiriza N., Preux P.M., Suykerbuyk P., Idro R. Onchocerciasis-associated epilepsy: From recent epidemiological and clinical findings to policy implications. Epilepsia Open. 2017;2:145–152. doi: 10.1002/epi4.12054. - DOI - PMC - PubMed
-
- Colebunders R., Njamnshi A.K., Menon S., Newton C.R., Hotterbeekx A., Preux P.M., Hopkins A., Vaillant M., Siewe Fodjo J.N. Onchocerca volvulus and epilepsy: A comprehensive review using the Bradford Hill criteria for causation. PLoS Negl. Trop. Dis. 2021;15:e0008965. doi: 10.1371/journal.pntd.0008965. - DOI - PMC - PubMed
-
- World Health Organization . Ending the Neglect to Attain the Sustainable Development Goals: A Road Map for Neglected Tropical Diseases 2021–2030. World Health Organization; Geneva, Switzerland: 2020.
Grants and funding
LinkOut - more resources
Full Text Sources